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Abstract: PURPOSE Total body irradiation (TBI) before allogeneic hematopoietic stem cell transplanta-
tion (HSCT) in pediatric patients with acute lymphoblastic leukemia (ALL) is efficacious, but long-term
side effects are concerning. We investigated whether preparative combination chemotherapy could replace
TBI in such patients. PATIENTS AND METHODS FORUM is a randomized, controlled, open-label,
international, multicenter, phase III, noninferiority study. Patients ฀ 18 years at diagnosis, 4-21 years
at HSCT, in complete remission pre-HSCT, and with an HLA-compatible related or unrelated donor
were randomly assigned to myeloablative conditioning with fractionated 12 Gy TBI and etoposide ver-
sus fludarabine, thiotepa, and either busulfan or treosulfan. The noninferiority margin was 8%. With
1,000 patients randomly assigned in 5 years, 2-year minimum follow-up, and one-sided alpha of 5%, 80%
power was calculated. A futility stopping rule would halt random assignment if chemoconditioning was
significantly inferior to TBI (EudraCT: 2012-003032-22; ClinicalTrials.gov: NCT01949129). RESULTS
Between April 2013 and December 2018, 543 patients were screened, 417 were randomly assigned, 212
received TBI, and 201 received chemoconditioning. The stopping rule was applied on March 31, 2019.
The median follow-up was 2.1 years. In the intention-to-treat population, 2-year overall survival (OS)
was significantly higher following TBI (0.91; 95% CI, 0.86 to 0.95; P < .0001) versus chemoconditioning
(0.75; 95% CI, 0.67 to 0.81). Two-year cumulative incidence of relapse and treatment-related mortality
were 0.12 (95% CI, 0.08 to 0.17; P < .0001) and 0.02 (95% CI, < 0.01 to 0.05; P = .0269) following TBI
and 0.33 (95% CI, 0.25 to 0.40) and 0.09 (95% CI, 0.05 to 0.14) following chemoconditioning, respec-
tively. CONCLUSION Improved OS and lower relapse risk were observed following TBI plus etoposide
compared with chemoconditioning. We therefore recommend TBI plus etoposide for patients > 4 years
old with high-risk ALL undergoing allogeneic HSCT.
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ab
stract
PURPOSE Totalbody irradiation (TBI)beforeallogeneichematopoieticstemcell transplantation (HSCT) inpediatric
patients with acute lymphoblastic leukemia (ALL) is efficacious, but long-term side effects are concerning. We
investigated whether preparative combination chemotherapy could replace TBI in such patients.
PATIENTS AND METHODS FORUM is a randomized, controlled, open-label, international, multicenter, phase III,
noninferiority study.Patients#18yearsatdiagnosis,4-21yearsatHSCT, incomplete remissionpre-HSCT,andwith
an HLA-compatible related or unrelated donor were randomly assigned to myeloablative conditioning with frac-
tionated 12 Gy TBI and etoposide versus fludarabine, thiotepa, and either busulfan or treosulfan. The noninferiority
marginwas 8%.With 1,000patients randomly assigned in5 years, 2-yearminimum follow-up, and one-sidedalpha
of 5%, 80%power was calculated. A futility stopping rule would halt random assignment if chemoconditioning was
significantly inferior to TBI (EudraCT: 2012-003032-22; ClinicalTrials.gov: NCT01949129).
RESULTS Between April 2013 and December 2018, 543 patients were screened, 417 were randomly assigned,
212 received TBI, and 201 received chemoconditioning. The stopping rule was applied onMarch 31, 2019. The
median follow-up was 2.1 years. In the intention-to-treat population, 2-year overall survival (OS) was significantly
higher following TBI (0.91; 95% CI, 0.86 to 0.95; P, .0001) versus chemoconditioning (0.75; 95% CI, 0.67 to
0.81). Two-year cumulative incidence of relapse and treatment-related mortality were 0.12 (95% CI, 0.08 to
0.17; P, .0001) and 0.02 (95% CI,, 0.01 to 0.05; P5 .0269) following TBI and 0.33 (95% CI, 0.25 to 0.40)
and 0.09 (95% CI, 0.05 to 0.14) following chemoconditioning, respectively.
CONCLUSION Improved OS and lower relapse risk were observed following TBI plus etoposide compared with
chemoconditioning. We therefore recommend TBI plus etoposide for patients . 4 years old with high-risk ALL
undergoing allogeneic HSCT.
J Clin Oncol 39:295-307. © 2020 by American Society of Clinical Oncology
Licensed under the Creative Commons Attribution 4.0 License
INTRODUCTION
Total body irradiation (TBI) is widely used in conditioning
regimens for patients with acute lymphoblastic leukemia
(ALL) undergoing allogeneic hematopoietic stem cell
transplantation (HSCT).1-3 For children with high-risk ALL,
an allogeneic HSCT from an HLA-identical sibling donor
(MSD) or HLA-compatible related or unrelated matched
donor (MD)4-7 or mismatched donor,8 conditioned with
TBI and etoposide has resulted in excellent overall and
leukemia-free survival.
A small, randomized, controlled trial found signif-
icantly higher event-free survival (EFS) with TBI,
etoposide, and cyclophosphamide versus busul-
fan, etoposide, and cyclophosphamide condition-
ing in pediatric ALL patients receiving an unrelated
donor HSCT, but a nonsignificant difference for
those receiving a related donor HSCT.9 Moreover, a
meta-analysis in patients with leukemia found
significantly lower treatment-related mortality
(TRM) with TBI-based versus busulfan-based
conditioning.10 However, TBI has lifelong adverse
effects. Impairment of growth, gonadal function,
and cognitive function, cataracts, and secondary
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New chemotherapeutic agents and combinations have
brought promise of fewer acute and late effects compared
with TBI that may outweigh the risk of leukemic reap-
pearance; in particular, fludarabine, thiotepa, targeted
busulfan, and treosulfan show promise.14-17 Head-to-head
prospective comparisons of chemoconditioning versus
TBI-containing regimens have not evaluated disease-free
survival or acute and long-term adverse events (AEs).
We conducted this prospective, randomized, controlled
trial to investigate whether optimal chemoconditioning




The For Omitting Radiation Under Majority age (FORUM)
study is an international, randomized, open-label, phase III
study (EudraCT 2012-003032-22; ClinicalTrials.gov:
NCT01949129). We report on the randomly assigned part,
conducted in 88 centers in 21 countries, with the primary
aim to test noninferiority of chemoconditioning versus TBI
with regard to overall survival (OS).
The study was designed by experts from ALL-Frontline and
Relapse study groups and members of several pediatric
transplantation groups. The Protocol (online only) and
statistical analysis plan were approved by the investiga-
tional review board or independent ethics committee and
national authorities for each center. The trial was performed
in accordance with the Declaration of Helsinki principles.
An Independent Data Monitoring Committee (IDMC) pe-
riodically reviewed safety and efficacy data. Per stopping
rules, random assignment would end if chemoconditioning
was significantly worse than control (5% level; log-rank
test). The IDMC recommended random assignment
suspension in December 2018. After extensive data ana-
lyses, we confirmed the findings and stopped random
assignment on March 31, 2019.
Patients
Patients eligible for random assignment had high-risk ALL,
were # 18 years old at initial diagnosis, 4-21 years old at
HSCT, had an indication for allogeneic HSCT, were in
complete morphological remission pre-HSCT, and had an
MSD or MD allelic matched at nine or 10 out of 10 HLA loci.
Exclusion criteria included prior HSCT, pre-HSCT cranial
radiation . 18 Gy at any time or . 12 Gy in the previous
24 months, pre-existing severe organ toxicities, pregnancy,
or secondary malignancy. Written informed consent was
provided by patients, parents, or legal guardians.
The recommended stem cell source was bone marrow or
cord blood from an MSD, or bone marrow, peripheral blood
stem cells, or cord blood from an MD.
Procedures
Patients were randomly assigned 1:1 either to TBI plus 60
mg/kg intravenous etoposide (1.8 g/m2; upper total dose
3.6 g) once on day 3 before HSCT or to intravenous flu-
darabine 30 mg/m2 once a day over 5 days, thiotepa 5 mg/
kg twice a day for 1 day, and either treosulfan 14 g/m2 once
a day for 3 days or busulfan over 4 days. National coor-
dinators chose busulfan or treosulfan. Busulfan was dosed
once, twice, or four times a day according to local guide-
lines, age, and body weight, commonly with therapeutic
drug monitoring and pharmacokinetic dose adjustment.
TBI was delivered from a linear accelerator at 12 Gy in six
fractions over 3 days with lung shielding at 10 Gy.
Graft-versus-host disease (GVHD) prophylaxis was con-
tingent upon donor type and stem cell source. MSD re-
cipients received cyclosporine A only, while MD recipients
also received methotrexate and antithymocyte globulin.
CONTEXT
Key Objective
Total body irradiation (TBI) before allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric patients with acute
lymphoblastic leukemia (ALL) is efficacious but can have long-term side effects. With a view to improving options for patients,
the FORUM randomized, controlled, open-label, international, multicenter, phase III trial was designed to investigate whether
preparative combination chemotherapy is noninferior to TBI.
Knowledge Generated
After random assignment of 417 pediatric patients with high-risk ALL, a futility stopping rule was applied because patients
receiving chemoconditioning with fludarabine, thiotepa, and either busulfan or treosulfan had inferior overall survival
(OS) to those receiving TBI plus etoposide. Two-year OS was 0.91 (95% CI, 0.86 to 0.95; P, .0001) following TBI versus
0.75 (95% CI, 0.67 to 0.81) following chemoconditioning.
Relevance
Of relevance to clinical practice, the authors recommend TBI plus etoposide for patients . 4 years old with high-risk ALL
undergoing allogeneic HSCT because of the higher survival and lower relapse risk observed in comparison with
chemoconditioning.
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Complete remission (CR) was defined as # 5% bone
marrow blasts and no evidence of extramedullary disease.
Minimal residual disease (MRD) in bone marrow was
assessed by flow cytometry or polymerase chain reaction
(PCR) in the 2 weeks before conditioning therapy. MRD
positivity was defined as . 1023 for flow cytometry or
. 1024 for PCR. Relapse was defined as $ 5% leukemic
blasts in bone marrow and/or detection in extramedullary
sites (eg, cerebrospinal fluid, testes, and ovary).
Clinicians assessed patients for AEs, adverse reactions,
serious AEs, and suspected expected or unexpected se-
rious adverse reactions per good clinical practice guide-
lines. AEs were graded by the National Cancer Institute
Common Terminology Criteria for Adverse Events, version
3.0. Serious AEs were fatal, life-threatening, or other
medically important serious events, leading to intensive
care unit admission (ie, grade 3-4). Acute and chronic
GVHD (aGVHD and cGVHD, respectively) were assessed at
each visit and graded as previously described.20
Outcomes
The primary end point was OS from random assignment
date. Death from any cause was considered an event.
Patients lost to follow-up without an event were censored at
last follow-up. Secondary end points included EFS, cu-
mulative incidence of relapse (CIR), TRM, aGVHD, cGVHD,
toxicity at day 100, and GVHD-free, relapse-free survival.
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FIG 1. Patient enrollment, random assignment, and adherence to protocol. Other: Variable modifications of the
given conditioning regimen due to medical reasons or center/parental decision. BU, busulfan; CHC, chemo-
conditioning; CR, complete remission; MD, human leukocyte antigen (HLA)–compatible related or unrelated
matched donor; MMD, mismatched donor; MSD, HLA-identical sibling donor; TBI, total body irradiation; Treo,
treosulfan.
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Statistical Analysis
The design was a noninferiority study with an 8% margin.
With a sample size of 1,000 patients randomly assigned in 5
years, 2-year minimum follow-up, and a one-sided alpha of
5%, 80% power was calculated. Early stopping made
follow-up too short for the intended primary analysis to be
feasible.
In FORUM, patients randomly assigned to TBI yet who
received chemoconditioning could be anticipated to be at
lower risk than patients randomly assigned to chemo-
conditioning yet who received TBI, meaning that a per-
protocol analysis might favor chemoconditioning. Ac-
cordingly, the ITT population was protocol-specified for
the primary analysis (see the Data Supplement, online
only). The results reported are from ITT analyses unless
otherwise indicated (data cutoff November 2019; random
assignment errors excluded; Fig 1). A secondary modified
as-treated analysis compared outcomes following TBI,
treosulfan-based chemoconditioning, and busulfan-based
chemoconditioning, excluding some protocol violations
(Fig 1). AEs were assessed in the modified as-treated
population.
OS, EFS, and GVHD-free, relapse-free survival were esti-
mated with Kaplan-Meier methodology and compared
using the logrank test. Two-year estimates and 95% CIs
used log transformation (a 5 5%). For the modified as-
treated and univariate analyses, pairwise comparisons were
performed if the global P value was significant. For mul-
tivariable analyses, Cox regression explored the impact of
risk factors and conditioning type on OS and EFS. In the
presence of monotone likelihoods, Firth correction was
used. Cox regression formally tested stratification factors
and interactions. Proportions of patients with grade 3-4
aGVHD and grade 3-4 AEs at day 100 were compared
using a x2 test. Cumulative incidences of relapse, TRM, and
cGVHD were estimated accounting for competing events
and compared using Gray’s test. Multivariable evaluation of
relapse incidence used the Fine and Graymodel. Subgroup
analyses were ad hoc. Median follow-up was estimated
using the inverse Kaplan-Meier method.
RESULTS
Between April 18, 2013, andMarch 31, 2019, a total of 543
patients were screened and 413 were randomly assigned
(Fig 1), mainly in Germany and France (Data Supplement).
Two hundred and twelve patients were randomly assigned
to TBI, and 201 were randomly assigned to chemo-
conditioning. Compliance with random assignment was
92%. Table 1 shows patient demographics and baseline
characteristics, which were well balanced between groups.
Sixty-five percent of participants were male, 72% had
B-cell precursor ALL, 73% had an MD, and 82% under-
went bone marrow transplantation. Fifty-four percent of
participants were in first complete remission (CR1) at
inclusion. Of patients assessed for MRD by PCR or flow
cytometry, 43% were positive and 57% were negative.
With a median follow-up of 2.1 years (range, 1 month to 6
years), OS was significantly higher following TBI versus
chemoconditioning, with a 2-year probability of OS of 0.91
(95% CI, 0.86 to 0.95) versus 0.75 (95% CI, 0.67 to 0.81),
respectively (P , .0001; Fig 2). Two-year EFS was sig-
nificantly higher following TBI versus chemoconditioning
(0.86 [95% CI, 0.79 to 0.90] v 0.58 [95% CI, 0.50 to 0.66],
respectively; P , .0001; Fig 2).
For 224 patients transplanted in CR1, 2-year OS and EFS
were 0.85 (95%CI, 0.79 to 0.90) and 0.80 (95%CI, 0.73 to
0.85), respectively, with both being significantly higher in
the TBI versus chemoconditioning arm (Data Supplement).
For 87 patients transplanted in second complete remission
(CR2) who relapsed . 30 months after diagnosis, 2-year
OS and EFS were 0.89 (95% CI, 0.78 to 0.95) and 0.69
(95% CI, 0.56 to 0.79), respectively; both end points were
significantly higher in the TBI versus chemoconditioning
arm (Data Supplement). In 69 patients with a BCR-ABL
mutation, KMT2A-AFF1 translocation, or blast cell hypo-
diploidy (, 45 chromosomes), 2-year EFS (but not OS) was
significantly higher with TBI versus chemoconditioning
(0.89 [95% CI, 0.71 to 0.97] v 0.60 [95% CI, 0.36 to 0.78],
respectively; P 5 .0182).
Two-year TRM was 0.02 (95% CI,, 0.01 to 0.05) following
TBI and 0.09 (95% CI, 0.05 to 0.14) following chemo-
conditioning (P 5 .0269). Of the TBI, busulfan-containing
chemoconditioning, and treosulfan-containing chemo-
conditioning groups, 7/194 (3.6%), 7/96 (7.3%), and 9/90
(10.0%) patients, respectively, died without relapse
(modified as-treated analysis; Table 2; Fig 2).
The results for OS, EFS, and TRM were superimposable in
modified as-treated analyses to those observed in the ITT
analyses. No significant differences between the two
chemoconditioning regimens were observed (Fig 2).
The most frequent reason for treatment failure was relapse,
commonly in bonemarrow (56/70 patients). Two-year CIRwas
0.12 (95% CI, 0.08 to 0.17) following TBI and 0.33 (95% CI,
0.25 to 0.40) following chemoconditioning (P , .0001;
Table 2; Fig 2). This difference remained significant when
patients were stratified by remission status (Data Supplement).
Of 67 patients who relapsed after HSCT, 38 died (12 after
TBI, 15 busulfan, and 11 treosulfan); 39 received salvage
therapy with curative intent. In patients who relapsed post-
transplant, there was no significant difference in OS be-
tween conditioning regimens (modified as-treated analysis;
Data Supplement).
There were no suspected unexpected serious adverse
reactions. Regimens were associated with substantial de-
grees of reported toxicity, as expected. The most common
grade 3-4 AEs at day 100 in all arms were cytopenia,
mucositis, nausea, and infection (Data Supplement).
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TABLE 1. Demographics and Clinical Characteristics of Patients According to Randomized Arm and Chemoconditioning Regimen
Patient and Disease Characteristic, n (%) All (N 5 413) TBI (n 5 212)
Chemoconditioning
Total (n 5 201) Busulfan (n 5 102) Treosulfan (n 5 99)
Sex
Male 267 (65%) 145 (68%) 122 (61%) 62 (61%) 60 (61%)
Female 146 (35%) 67 (32%) 79 (39%) 40 (39%) 39 (39%)
Age (years)
4-6 56 (14%) 34 (16%) 22 (11%) 9 (9%) 13 (13%)
. 6-10 141 (34%) 66 (31%) 75 (37%) 42 (41%) 33 (33%)
. 10-14 106 (26%) 64 (30%) 42 (21%) 23 (23%) 19 (19%)
. 14 110 (27%) 48 (23%) 62 (31%) 28 (27%) 34 (34%)
Immunophenotype
B-cell precursor ALL 297 (72%) 153 (72%) 144 (72%) 83 (81%) 61 (62%)
T-cell ALL 94 (23%) 48 (23%) 46 (23%) 18 (18%) 28 (28%)
Biphenotypic 18 (4%) 11 (5%) 7 (3%) 1 (1%) 6 (6%)
Unknown 4 (1%) 0 (0%) 4 (2%) 0 (0%) 4 (4%)
MRD pre-HSCTa
MRD-negative (PCR) 135 (33%) 72 (34%) 63 (31%) 40 (39%) 23 (23%)
MRD-positive (PCR) 132 (32%) 61 (29%) 71 (35%) 31 (30%) 40 (40%)
MRD-negative (flow cytometry) 57 (14%) 32 (15%) 25 (12%) 20 (20%) 5 (5%)
MRD-positive (flow cytometry) 12 (3%) 9 (4%) 3 (1%) 3 (3%) 0 (0%)
BCR-ABL
Yes 30 (7%) 12 (6%) 18 (9%) 10 (10%) 8 (8%)
ETV6-RUNX1
Yes 46 (11%) 16 (8%) 30 (15%) 18 (18%) 12 (12%)
KMT2A-AFF1
Yes 11 (3%) 4 (2%) 7 (3%) 3 (3%) 4 (4%)
Hyperdiploid (. 50 chromosomes)
Yes 70 (17%) 39 (18%) 31 (15%) 18 (18%) 13 (13%)
Hypodiploid (, 45 chromosomes)
Yes 31 (8%) 19 (9%) 12 (6%) 7 (7%) 5 (5%)
HSCT performed
No 6 (1%) 2 (1%) 4 (2%) 2 (2%) 2 (2%)
Yes 407 (99%) 210 (99%) 197 (98%) 100 (98%) 97 (98%)
Conditioning regimen
TBI 202 (50%) 194 (92%) 8 (4%) 1 (1%) 7 (7%)
Busulfan-based 99 (24%) 3 (1%) 96 (49%) 95 (95%) 1 (1%)
Treosulfan-based 93 (23%) 3 (1%) 90 (46%) 1 (1%) 89 (92%)
Otherb 13 (3%) 10 (5%) 3 (1%) 3 (3%) 0 (0%)
Donor
MSD 108 (27%) 54 (26%) 54 (27%) 34 (34%) 20 (21%)
MD 299 (73%) 156 (74%) 143 (73%) 66 (66%) 77 (79%)
Remission status
CR1 225 (54%) 118 (56%) 107 (53%) 47 (46%) 60 (61%)
CR2 164 (40%) 85 (40%) 79 (39%) 46 (45%) 33 (33%)
CR3 18 (4%) 7 (3%) 11 (5%) 7 (7%) 4 (4%)
(continued on following page)
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In the modified as-treated analysis, TRM occurred in 7/
194 patients following TBI, 7/96 patients after busulfan-
based chemoconditioning, and 9/90 patients after
treosulfan-based chemoconditioning. The most common
causes were infection, organ toxicity, or GVHD, with no
significant difference between conditioning regimens
(Data Supplement).
There was no significant difference in the proportion of
patients experiencing aGVHD or cGVHD between arms
(Table 2). Of 396 patients evaluable for aGVHD, 263
TABLE 1. Demographics and Clinical Characteristics of Patients According to Randomized Arm and Chemoconditioning Regimen (continued)
Patient and Disease Characteristic, n (%) All (N 5 413) TBI (n 5 212)
Chemoconditioning
Total (n 5 201) Busulfan (n 5 102) Treosulfan (n 5 99)
Stem cell sourcec
Bone marrow 337 (82%) 174 (82%) 163 (81%) 78 (76%) 85 (86%)
Peripheral bloodd 51 (12%) 25 (12%) 26 (13%) 14 (14%) 12 (12%)
Cord blood 16 (4%) 9 (4%) 7 (3%) 7 (7%) 0 (0%)
Characteristics of first relapse in CR2 patients, n (%)e
Bone marrow isolated 111 (68%) 53 (62%) 58 (73%) 29 (63%) 29 (88%)
Other isolated 14 (9%) 7 (8%) 7 (9%) 5 (11%) 2 (6%)
Combined 38 (23%) 24 (28%) 14 (18%) 12 (26%) 2 (6%)
Time of relapse from first diagnosis (months)
, 18 22 (13%) 16 (19%) 6 (8%) 1 (2%) 5 (15%)
18-30 55 (34%) 27 (32%) 28 (35%) 15 (33%) 13 (39%)
. 30 87 (53%) 42 (49%) 45 (57%) 30 (65%) 15 (45%)
Abbreviations: ALL, acute lymphoblastic leukemia; CR1, first complete remission; CR2, second complete remission; CR3, third complete remission; HSCT,
hematopoietic stem cell transplantation; MD, HLA-compatible related or unrelated matched donor; MRD, minimal residual disease; MSD, HLA-identical
sibling donor; PCR, polymerase chain reaction; TBI, total body irradiation.
aMRD was defined as . 1023 for flow cytometry and . 1024 for PCR; data missing for 77 patients.
bOther: variable modifications of the given conditioning regimen because of medical reasons or center/patient decision including two patients who withdrew
consent to collect data.
cData missing for three patients.
dIncluding two patients receiving stem cells from both bone marrow and peripheral blood (one in the TBI group and one in the treosulfan group).
eData missing for one patient.
Patients Eval. Deaths 2-year OS
TBI 212 209 19 0.91 (0.86-0.95)
CHC 201 200 49 0.75 (0.67-0.81)
212 173 105 65 27
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Patients Eval. Deaths 2-year OS
TBI 194 194 19 0.91 (0.85-0.94)
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P = .0025
TBI vs. BU: P = .0009
TBI vs. TREO: P = .0041
BU vs. Treo: P = .6152
FIG 2. Primary end point: Overall survival. BU, busulfan; CHC, chemo-conditioning; CIR, cumulative incidence of relapse; EFS,
event-free survival; OS, overall survival; TBI, total body irradiation; TREO, treosulfan; TRM, treatment-related mortality.
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TABLE 2. Primary and Secondary End Points According to Conditioning Regimen
Intention-to-Treat Population Modified As-Treated Population
TBI CHC P TBI Busulfan CHC Treosulfan CHC P
Primary end point
Death
Deaths/patients 19/212 49/201 19/194 22/96 20/90





31/212 72/201 30/194 30/96 33/90
2-year EFS (95% CI) 0.86 (0.79 to 0.90) 0.58 (0.50 to 0.66) ,.0001 0.85 (0.79 to 0.90) 0.64 (0.52 to 0.74) 0.58 (0.45 to 0.69) ,.0001
Relapse
Relapses/patients 24/212 55/200 23/194 23/96 24/90
2-year CIR (95% CI) 0.12 (0.08 to 0.17) 0.33 (0.25 to 0.40) ,.0001 0.12 (0.08 to 0.17) 0.30 (0.19 to 0.41) 0.31 (0.20 to 0.42) .0032
Nonleukemic death
Death in CR/patients 7/212 17/200 7/194 7/96 9/90
2-year TRM (95% CI) 0.02 (,0.01 to 0.05) 0.09 (0.05 to 0.14) .0269 0.03 (0.01 to 0.06) 0.06 (0.03 to 0.13) 0.12 (0.06 to 0.20) .1103
Acute GVHD by day 100
Evaluablea 203/212 193/201 188/194 96/96 87/90
Grade 0 or 1 127 (63%) 136 (70%) 115 (61%) 65 (68%) 67 (77%)
Grade 2 51 (25%) 39 (20%) 49 (26%) 23 (24%) 11 (12%)
Grade 3 or 4 25 (12%) 18 (9%) .3393 24 (13%) 8 (8%) 9 (10%) .5148
Chronic GVHD by 2 years
cGVHD/event without cGVHD/patients 29/26/208 18/60/193 29/25/193 11/26/94 7/29/89
2-y cumulative incidence of cGVHD (95% CI) 0.16 (0.11 to 0.21) 0.11 (0.07 to 0.16) .1456 0.17 (0.12 to 0.23) 0.13 (0.07 to 0.21) 0.09 (0.04 to 0.17) .2255
2-y cumulative incidence of event
without cGVHD (95% CI)
0.12 (0.08 to 0.18) 0.36 (0.23 to 0.43) ,.0001 0.12 (0.08 to 0.18) 0.33 (0.23 to 0.45) 0.36 (0.26 to 0.47) .0002
GVHD and relapse
Events/patients 54/212 87/198 52/194 38/96 40/90
2-year GRFS (95% CI) 0.72 (0.65 to 0.79) 0.51 (0.43 to 0.59) .0003 0.71 (0.63 to 0.77) 0.54 (0.41 to 0.64) 0.51 (0.39 to 0.62) .0106
Nonhematologic AEs of grade 3 or 4
Evaluable 205 195 190 96 89
Grade 3 or 4 175 (85%) 160 (82%) .3690 163 (86%) 75 (78%) 75 (84%) .2500
Abbreviations: AE, adverse event; aGVHD, acute graft versus host disease; cGVHD, chronic graft versus host disease; CHC, chemoconditioning; CIR, cumulative incidence of relapse; CR, complete
remission; EFS, event-free survival; GRFS, GVHD-free, relapse-free survival; GVHD, graft versus host disease; OS, overall survival; TBI, total body irradiation; TRM, treatment-related mortality.
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experienced no or grade 1 aGVHD, 90 developed grade 2
aGVHD, and 43 developed grade 3-4 aGVHD by day 100
(Table 2).
Two-year EFS across the whole study population stratified
by aGVHD grade 0-1, 2, and 3-4 was 0.72 (95% CI, 0.64 to
0.78), 0.85 (95% CI, 0.73 to 0.92), and 0.54 (95% CI, 0.36
to 0.69), respectively (P 5 .0041). Two-year TRM was
significantly higher for patients with grade 3-4 aGVHD
versus those with grade 0-1 or 2 (0.22 [95% CI, 0.10 to
0.37], 0.04 [95% CI, 0.02 to 0.08], and 0.02 [95%
CI, , 0.01 to 0.07], respectively; P , .0001).
No significant difference in the incidence and severity of
aGVHD was observed when patients were stratified by
donor type or conditioning regimen (Data Supplement).
Two-year cumulative incidence of cGVHD did not signifi-
cantly differ between arms (Table 2).
Patients Eval. TRM 2-year TRM
TBI 212 209 7 0.02 (<0.01-0.05)
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Patients Eval. TRM 2-year TRM
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Patients Eval. Events 2-year EFS
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Patients Eval. Events 2-year EFS
TBI 194 194 30 0.85 (0.79-0.90)
BU 96 96 30 0.64 (0.52-0.74)
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Patients Eval. Relapses 2-year CIR
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FIG 3. Secondary end points. BU, busulfan; CHC, chemo-conditioning; CIR, cumulative incidence of relapse; EFS,
event-free survival; OS, overall survival; TBI, total body irradiation; TREO, treosulfan; TRM, treatment-related
mortality.
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The probability of GVHD-free, relapse-free survival at 2
years was 0.72 (95% CI, 0.65 to 0.79) following TBI and
0.51 (95% CI, 0.43 to 0.59) following chemoconditioning
(P , .0003; Table 2; Data Supplement).
In univariate analyses, MSD and CR1 significantly
predicted better OS and EFS. Female patients had a
lower probability of EFS (n5 145; 0.64 [95% CI, 0.54 to
0.72]) versus male patients (n 5 264; 0.77 [95% CI,
0.70 to 0.82]; P 5 .016) (Data Supplement). Analysis of
OS by risk factor and conditioning regimen is shown in
Figure 4 and the Data Supplement. A significant in-
teraction was observed when age and conditioning
therapy were analyzed, with the beneficial effect of TBI
on OS strongest in patients of age 6-14 years. No sig-
nificant interactions between risk factors and condi-
tioning regimens were observed for EFS (Data
Supplement).
In multivariable analyses, conditioning regimen reached
statistical significance for OS (hazard ratio [HR], 3.1; 95%
CI, 1.7 to 5.7; P 5 .0003), EFS (HR, 2.8; 95% CI, 1.7-4.6;
P , .0001), and relapse rate (HR, 2.5; 95% CI, 1.4 to 4.4;
P 5 .0001) (Table 3). EFS was lower for patients trans-
planted in CR2 versus CR1 (HR, 1.7; 95% CI, 1.0-2.7; P5
.0371). Surprisingly, the presence or absence of MRD
positivity pretransplant assessed by flow cytometry or PCR
did not significantly influence OS or EFS in subgroup or
multivariable analyses.
DISCUSSION
FORUM is the largest international, multicenter, ran-
domized trial comparing TBI plus etoposide versus
myeloablative chemoconditioning regimens (consisting of
fludarabine, thiotepa, and either intravenous busulfan or
treosulfan) in pediatric patients with high-risk ALL. De-
spite several hurdles in initiating the trial in over 20
countries and 5 continents, FORUM was made possible
by collaboration between international study groups.
Patients underwent allogeneic HSCT according to
standardized transplant indications, donor selection
criteria, stem cell source, GVHD prophylaxis, and con-
ditioning regimen. Investigators were given recommen-
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FIG 4. Forrest plot showing subgroup analyses of overall survival by risk factor and conditioning regimen (ITT population). ALL, acute lym-
phoblastic leukaemia; BM, bone marrow, CR1, first complete remission (below 5% of morphological blasts in bone marrow; no active
extramedullary disease); CR2, second complete remission; CR3, third complete remission; HSCT, haematopoietic stem cell transplantation;
MD, human leukocyte antigen (HLA)-compatible (nine or 10 out of 10 allelic matches) related or unrelated matched donor; MRD, minimal
residual disease; MSD, HLA-identical sibling donor; TBI, total body irradiation.
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reduce MRD pretreatment and post-transplant. Strong
random assignment compliance, rigorous data collec-
tion, and careful, prompt interim analysis allowed de-
tection of the inferiority of chemoconditioning to TBI plus
etoposide.
In a retrospective trial, it was shown that chemo-
conditioning can supplant TBI at least in some young
patients with ALL and favorable prognosis pre-HSCT (CR1
or age, 12 years).15,21 In a recent retrospective analysis of
over 3,000 pediatric patients with ALL, no significant dif-
ference in OS was observed between patients in CR1
transplanted after TBI versus chemoconditioning; however,
in patients transplanted in CR2, the TBI arm had signifi-
cantly better OS, EFS, relapse incidence, and TRM.22 A
similar trend was observed in our subgroup analyses;
however, our study was not powered to assess statistical
significance in a sample size of 413 patients. Highly en-
couraging 2-year OS and EFS of 0.91 and 0.91, respec-
tively, were observed for patients transplanted in CR1 after
TBI, which we believe is the highest survival rate reported in
HSCT trials in childhood ALL.
Patients receiving TBI had a significantly lower risk of re-
lapse and TRM than those given chemoconditioning. This
resulted in early termination of random assignment.
The majority of post-HSCT leukemic relapses in children
occur within 24 months; thus, a dramatic change in
Kaplan-Meier estimates of relapse with further follow-up is
unlikely. In part, the difference in relapse risk between arms
could be detected early due to the low rate of TRM (higher
survival rates yield a larger pool of patients to potentially
relapse). There was a plateau in the rate of relapse with TBI
plus etoposide after 2.5 years, whereas an extended re-
lapse cascade was apparent with chemoconditioning. The
lack of an asymptote in relapse rate after chemo-
conditioning suggests that between-group differences may
continue to widen over time. It is unlikely that secondary
malignancies after TBI (which in some studies have caused
survival curves to cross)23 could jeopardize the survival
advantage of TBI plus etoposide.
Randomized, international studies are a crucial, up-to-date
evidence base supporting clinicians and patients in bal-
ancing treatment risks and benefits. We recommend TBI
plus etoposide conditioning for patients . 4 years old with
high-risk ALL undergoing allogeneic HSCT. However, TBI is
not always an option because of lack of facilities, young age,
or comorbidities. Fludarabine, thiotepa, and either busul-
fan or treosulfan have shown high efficacy compared with
other preparative regimens in previous studies of pediatric
HSCT.16,24 Moreover, TRM with chemoconditioning in
FORUM was low versus that previously reported.25,26
However, relapse incidence was still high, and the best
chemotherapy-based preparative regimen for patients in-
eligible for TBI is unknown.22,27,28








HR (95% CI) P HR (95% CI) P HR (95% CI) P
Arm
CHC v TBI 3.1 (1.7 to 5.7) .0003 2.8 (1.7 to 4.6) ,.0001 2.5 (1.4 to 4.4) ,.0001
Donor
MSD v MD 0.8 (0.4 to 1.4) .3851 0.8 (0.5 to 1.4) .5073 0.7 (0.4 to 1.1) .1224
Remission phase (v CR1)
CR2 1.5 (0.8 to 2.7) .2078 1.7 (1.0 to 2.7) .0371 1.7 (1.0 to 3.1) .0572
CR3 0.7 (0.1 to 2.9) .5785 0.6 (0.2 to 2.2) .4834 0.3 (0.04 to 2.5) .2684
MRDa
Positive v negative 1.4 (0.8 to 2.4) .2904 1.4 (0.9 to 2.3) .1192 1.4 (0.8 to 2.4) .2602
Age
$10 years v ,10 years 1.8 (1 to 3.1) .0480 1.5 (1 to 2.4) .0799 1.2 (0.7 to 2.14) .4327
Immunophenotype (v BCP)
T-ALL 1.1 (0.5 to 2.3) .8968 0.8 (0.4 to 1.6) .4915 0.9 (0.4 to 1.9) .7080
Other 1.1 (0.1 to 8) .9584 0.6 (0.1 to 4.4) .6160 NA ..
Abbreviations: BCP, B-cell precursor acute lymphoblastic leukemia; CHC, chemoconditioning; CR, complete remission; CR1, first complete remission;
CR2, second complete remission; CR3, third complete remission; EFS, event-free survival; HR, hazard ratio; MD, HLA-compatible related or unrelated
matched donor; MRD, minimal residual disease; MSD, HLA-identical sibling donor; NA, not applicable; OS, overall survival; PCR, polymerase chain reaction;
T-ALL, T-cell acute lymphoblastic leukemia; TBI, total body irradiation; TRM, treatment-related mortality.
aDefined as . 1023 for flow cytometry and . 1024 for PCR.
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Despite variations including center size and heterogeneity
of supportive care among the participating sites, TRM in-
cidence was lower in FORUM than in other reports.25,29,30
Furthermore, established risk factors for post-transplant
relapse (ie, age at transplantation, leukemic phenotype
and molecular aberrations, site of relapse, MRD pre-
transplant, donor type, and stem cell source)31-33 did not
significantly impact outcomes. In multivariable analyses,
only remission status (ie, CR1 v CR2 or above) and con-
ditioning type influenced OS and EFS. Add-on studies will
explore the impact of busulfan, treosulfan, and antithy-
mocyte globulin pharmacokinetics and pharmacoge-
nomics on relapse rate.
We and others have previously demonstrated that high
MRD levels pretransplant increased post-transplant relapse
risk.34,35 Surprisingly, MRD level did not affect EFS in
FORUM, probably because of patients’ favorable MRD
profile. It was a strong mission in our study to reduce MRD
to below 1023 with several treatment modalities including
bispecific antibodies, inotuzumab, nelarabine, and other
individualized methods, always bearing in mind that ad-
ditional chemotherapy might increase the risk of TRM
(although this was not the case). Indeed, most patients had
undetectable or very low levels of MRD in pretransplant
marrow aspirates. Further analyses by pretransplant MRD
will be conducted.
In FORUM, relapse after transplant was associated with a
low possibility of cure, which negated our premise that such
patients would be salvageable by a second HSCT using
TBI. This approach was associated with high TRM. The low
number of patients who received chimeric antigen receptor
T-cell therapy for post-transplant relapse (n5 10) does not
allow conclusions to be drawn. However, emerging cell and
immune therapies may offer the opportunity for rescue
going forward, with potential for deep remissions and
higher survival.
The higher probability of EFS observed in patients expe-
riencing grade 2 aGVHD suggests that—at moderate
severity—aGVHD is associated with a graft-versus-leukemia
effect and protects from leukemia recurrence.34-36
Our findings cannot be generalized to centers with limited
or no access to TBI. Another limitation is the relatively short
median follow-up (2.1 years). Early random assignment
closure limited sample size, making the prespecified pri-
mary analysis infeasible. The conditional power of the study
was assessed to explore the likelihood that noninferiority
could be concluded with a sample size of 1,000; which was
found to be extremely low.
Recruitment without random assignment is ongoing
as several questions of special interest require longer
follow-up, that is, effect of conditioning on gonadal func-
tion, final height, organ functions, individual genetic vari-
abilities, and secondary malignancies.12,37-39
The composite end point of 2-year GVHD-free, relapse-free
survival of 72% (95% CI, 65%-78%) following TBI plus
etoposide and 51% (95% CI, 43% to 58%; P 5 .0003)
following chemoconditioning might be a benchmark for
future investigations,accountingforsecondmalignancyrisk.
In conclusion, pediatric patients with high-risk ALL who
received myeloablative TBI plus etoposide prior to HSCT
had a significantly better survival and lower relapse risk
and TRM versus patients who received myeloablative
chemotherapy.
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